Targeted therapy in renal cell carcinoma – moving from molecular agents to specific immunotherapy

Česká verzia

Authors: J. Bedke; A. Stenzl
Authors place of work: Eberhard Karls University Tübingen ; Dept. of Urology
Published in the journal: Urol List 2014; 12(1): 39-45

Summary

Non‑ specific immunotherapy has been for a long time a standard treatment option for patients with metastatic renal cell carcinoma, but was redeemed by specific targeted molecular therapies, namely the VEGF and mTOR inhibitors. After moving treatment of mRCC to specific molecular agents with a well defined mode of action, immunotherapy still needs this further development to increase its accuracy. Nowadays, an evolution from a rather non‑specific cytokine treatment to sophisticated targeted approaches in specific immunotherapy led to a re‑launche of immunotherapy in clinical studies. Recent stepsin the developments of immunotherapy strategies are discussed in this review with a special focus on peptide vaccination which aims at a tumor targeting by specific T lymphocytes. In addition, different combinatory strategies with immunomodulating agents like cyclophosphamide or sunitinib are outlined and the effects of immune checkpoint modulators as anti‑CTLA‑ 4 or PD1 antibodies are discussed.

Key words:
renal cell carcinoma, tyrosine kinase inhibitor, immune therapy, vaccination, IMA-901

Zdroje

1. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997; 20(4): 416– 418.

2. Dengjel J Nastke MD, Gouttefangeas C et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006; 12(14 Pt 1): 4163– 4170.

3. Sáenz‑ López P, Gouttefangeas C, Hennenlotter J et al. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 2010; 75(2): 110– 118. doi: 10.1111/ j.1399– 0039.2009.01409.x.

4. Attig S, Hennenlotter J, Pawelec G et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009; 69(21): 8412– 8419. doi: 10.1158/ 0008– 5472.CAN‑ 09– 0852.

5. Schendel DJ, Gansbacher B, Oberneder R et al. Tumor‑ specific lysis of human renal cell carcinomas by tumor‑ infiltrating lymphocytes. I. HLA‑A2– restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151(8): 4209– 4220.

6. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58(3): 398– 406. doi: 10.1016/ j.eururo.2010.06.032.

7. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high‑dose and low‑dose interleukin‑2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21(16): 3127– 3132.

8. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11(10): 3714– 3721.

9. Pantuck AJ, Fang Z, Liu X et al. Gene expression and tissue microarray analysis of interleukin‑2 complete responders in patients with metastatic renal cell carcinoma. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (16 Suppl): 4535.

10. Ahmadzadeh M, Rosenberg SA. IL‑2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107(6): 2409– 2414.

11. van der Vliet HJ, Koon HB, Yue SC et al. Effects of the administration of high‑dose interleukin‑2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 2007; 13(7): 2100– 2108.

12. Kruck S, Bedke J, Kuczyk MA et al. Second‑line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2012; 12(6): 777– 785. doi: 10.1586/ era.12.43.

13. Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2012; 23 (Suppl 7): 65– 71.

14. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal‑ cell carcinoma. N Engl J Med 2007; 356(2): 115– 124.

15. Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111(12): 5610– 5620. doi: 10.1182/ blood‑ 2007– 02– 075945.

16. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type‑ 1 immune suppression and decreases T‑ regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14(20): 6674– 6682. doi: 10.1158/ 1078– 0432.CCR‑ 07– 5212.

27. Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid‑ derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15(6): 2148– 2157. doi: 10.1158/ 1078– 0432.CCR‑ 08– 1332.

18. Porta C, Paglino C, Imarisio I et al. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2011; 2: 333– 338.

19. Abraham RT, Wiederrecht GJ. Immuno-pharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483– 510.

20. Rammensee HG, Falk K, Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993; 11: 213– 244.

21. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254(5038): 1643– 1647.

22. Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient‑ individual antitumor vaccines. Cancer Res 2002; 62(20): 5818– 5827.

23. Seremet T, Brasseur F, Coulie PG. Tumor‑ specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 2011; 17(5): 325– 330. doi: 10.1097/ PPO.0b013e3182326004.

24. Brookman‑ May S, Burger M, Wieland WF et al. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines 2011; 10(6): 837– 852. doi: 10.1586/ erv.11.64.

25. Wierecky J, Müller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide‑ pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66(11): 5910– 5918.

26. Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer – when TKIs are not enough. Nat Rev Clin Oncol 2009; 6(8): 478– 487. doi: 10.1038/ nrclinonc.2009.91.

27. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal‑ cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363(9409): 594– 599.

28. Wood C, Strivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC‑ 96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open‑ label, randomised phase III trial. Lancet 2008; 372(9633): 145– 154. doi: 10.1016/ S0140– 6736(08)60697– 2.

29. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012; 23 (Suppl 8): 35– 40. doi: 10.1093/ annonc/ mds261.

30. Engels B, Noessner E, Frankenberger B et al. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 2005; 16(7): 799– 810.

31. Britten CM, Goutefangeas C, Welters MJ et al. The CIMT‑ monitoring panel: a two‑step approach to harmonize the enumeration of antigen‑ specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57(3): 289– 302.

32. van der Burg SH, Kalos M, Gouttefangeas C et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011; 3(108): 108– 144. doi: 10.1126/ scitranslmed.3002785.

33. Welters MJ, Gouttefangeas C, Ramwadhdoebe TH et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 2012; 61(7): 967– 978. doi: 10.1007/ s00262– 012– 1282– 9.

34. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single‑dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18(8): 1254– 1261. doi: 10.1038/ nm.2883.

35. Welters MJ, Kenter GG, de Vos van Steenwijk PJ et al. Success or failure of vaccination for HPV16– positive vulvar lesions correlates with kinetics and phenotype of induced T‑ cell responses. Proc Natl Acad Sci U S A 2010; 107(26): 11895– 11899. doi: 10.1073/ pnas.1006500107.

36. Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA‑ 5T4: a randomized, double‑blind, placebo‑ controlled phase III study. Clin Cancer Res 2010; 16(22): 5539– 5547. doi: 10.1158/ 1078– 0432.CCR‑ 10– 2082.

37. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression‑free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31): 4722– 4729. doi: 10.1200/ JCO.2010.28.6963.

38. Feyerabend S, Stevanovic S, Gouttefangeas C et al.Novel multi‑peptide vaccination in Hla‑ A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69(9): 917– 927. doi: 10.1002/ pros.20941.

39. Bedke J, Laske K, Feyerabend S et al. Clinical and immunological monitoring of a multi‑peptide vaccination trial in patients with stage III renal cell carcinoma. European Urology 2012; 11 (Suppl 1): e76– e76a.

40. Uemura H, Fujimoto K, Tanaka M et al. A phase I trial of vaccination of CA9– derived peptides for HLA‑A24– positive patients with cytokine‑ refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12(6): 1768– 1775.

41. Rosenberg SA, Yang JC, Schwartzentruber DJ et al.Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999; 163(3): 1690– 1695.

42. Weber J, Sondak VK, Scotland R et al. Granulocyte‑ macrophage‑ colony‑ stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003; 97(1): 186– 200.

43. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117(5): 1167– 1174.

44. Kusmartsev S, Su Z, Heisen A et al. Reversal of myeloid cell‑ mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008, 14(24): 8270– 8278. doi: 10.1158/ 1078– 0432.CCR‑ 08– 0165.

45. Mantovani A, Allavena P, Sica A et al. Cancer‑related inflammation. Nature 2008; 454(7203): 436– 444. doi: 10.1038/ nature07205.

46. Murdoch C, Muthana M, Coffelt SB et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8(8): 618– 631. doi: 10.1038/ nrc2444.

47. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711– 723. doi: 10.1056/ NEJMoa1003466.

48. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti‑CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30(8): 825– 830.

49. Study of Nivolumab (BMS‑ 936558) vs. Everolimus in Pre‑Treated Advanced or Metastatic Clear‑ cell Renal Cell Carcinoma (CheckMate 025). [online]. Available from: http:/ / clinicaltrials.gov/ ct2/ show/ NCT01668784.

50. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti‑PD‑ 1 antibody in cancer. N Engl J Med 2012; 366(26): 2443– 2454. doi: 10.1056/ NEJMoa1200690.

51. El Mir S, Triebel F. A soluble lymphocyte activation gene‑ 3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 2000; 164(11): 5583– 5589.

52. Brignone C, Escudier B, Grygar C et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 2009; 15(19): 6225– 6231. doi: 10.1158/ 1078– 0432.CCR‑ 09– 0068.

53. Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon alfa‑2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28(13): 2144– 2150. doi: 10.1200/ JCO.2009.26.7849.

54. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28(13): 2137– 2143.

55. Nivolumab (BMS‑ 936558;,MDX‑ 1106) InCombination With Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC). Available from: http:/ / clinicaltrials.gov/ ct2/ show/ NCT01472081.

56. Figlin RA, Nicolette CA, Amin A et al. Monitoring T‑ cell responses in a phase II study of AGS‑ 003, an autologous dendritic cell‑based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 2011; 29 (Suppl): 2532.

57. IMA901 in Patients Receiving Sunitinib for Advanced/ Metastatic Renal Cell Carcinoma. Available from: http:/ / clinicaltrials.gov/ ct2/ show/ NCT01265901.